Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Sponsor: Baxalta now part of Shire
Listed as NCT00157079, this PHASE3 trial focuses on Immune Thrombocytopenic Purpura (ITP) and Kawasaki Syndrome and remains completed. Sponsored by Baxalta now part of Shire, it has been updated 10 times since 2002, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Nov 2017 [monthly]
Completed PHASE3
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .